BLTE insider transaction filings
BELITE BIO, INC — 31 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen BLTE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Lin Yu-Hsin — Chief Executive Officer, Director | Sale (S): 142 @ $180 · Sale (S): 223 @ $180.57 | EDGAR |
| 2026-08-14 | 4 | Chuang Hao-Yuan — Chief Financial Officer, Director | Sale (S): 144 @ $180 · Sale (S): 223 @ $180.57 | EDGAR |
| 2026-06-22 | 4 | Scholl Hendrik Peter — Chief Medical Officer | Sale (S): 96 @ $143.90 · Sale (S): 3,748 @ $144.66 · Sale (S): 4,861 @ $145.43 · Sale (S): 1,199 @ $146.24 · Sale (S): 96 @ $147.11 | EDGAR |
| 2026-06-17 | 4 | Scholl Hendrik Peter — Chief Medical Officer | Sale (S): 2,054 @ $137.61 · Sale (S): 784 @ $138.18 · Sale (S): 3,140 @ $139.57 · Sale (S): 540 @ $140.58 · Sale (S): 100 @ $141.83 · Sale (S): 450 @ $142.20 · +2 more | EDGAR |
| 2026-05-08 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 226 @ $152.45 · Sale (S): 428 @ $153.56 · Sale (S): 3 @ $154.61 · Sale (S): 9 @ $155.25 | EDGAR |
| 2026-05-07 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 8 @ $151.57 · Sale (S): 424 @ $152.67 · Sale (S): 128 @ $153.42 · Sale (S): 240 @ $154.41 · Sale (S): 100 @ $155.97 · Sale (S): 100 @ $156 | EDGAR |
| 2026-05-06 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 120 @ $153.92 · Sale (S): 363 @ $154.44 · Sale (S): 173 @ $155.48 · Sale (S): 121 @ $156.53 · Sale (S): 155 @ $157.29 · Sale (S): 68 @ $158.11 | EDGAR |
| 2026-05-05 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 32 @ $153.50 · Sale (S): 236 @ $154.24 · Sale (S): 325 @ $155.21 · Sale (S): 235 @ $156.57 · Sale (S): 172 @ $157.49 | EDGAR |
| 2026-05-04 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 52 @ $153.89 · Sale (S): 288 @ $154.38 · Sale (S): 346 @ $155.48 · Sale (S): 82 @ $156.24 · Sale (S): 106 @ $157.45 · Sale (S): 65 @ $158.35 · +2 more | EDGAR |
| 2026-05-01 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 42 @ $155.68 · Sale (S): 517 @ $156.59 · Sale (S): 340 @ $157.37 · Sale (S): 101 @ $158.15 | EDGAR |
| 2026-04-30 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 278 @ $154.58 · Sale (S): 259 @ $155.52 · Sale (S): 339 @ $156.43 · Sale (S): 102 @ $157.39 · Sale (S): 22 @ $158.19 | EDGAR |
| 2026-04-29 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 12 @ $154.65 · Sale (S): 8 @ $155.36 · Sale (S): 53 @ $156.61 · Sale (S): 222 @ $157.49 · Sale (S): 62 @ $158.71 · Sale (S): 380 @ $159.42 · +3 more | EDGAR |
| 2026-04-28 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 44 @ $160.83 · Sale (S): 280 @ $161.62 · Sale (S): 231 @ $162.38 · Sale (S): 409 @ $163.56 · Sale (S): 36 @ $164.07 | EDGAR |
| 2026-04-27 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 74 @ $157.86 · Sale (S): 190 @ $158.65 · Sale (S): 375 @ $159.46 · Sale (S): 330 @ $160.40 · Sale (S): 28 @ $161.22 · Sale (S): 3 @ $162.53 | EDGAR |
| 2026-04-24 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 267 @ $164.47 · Sale (S): 158 @ $165.38 · Sale (S): 127 @ $166.56 · Sale (S): 373 @ $167.37 · Sale (S): 54 @ $168.43 · Sale (S): 21 @ $169.56 | EDGAR |
| 2026-04-23 | 4 | Lin Yu-Hsin — Chief Executive Officer, Director | Other (J): 10,000 @ $0 | EDGAR |
| 2026-04-23 | 4 | Scholl Hendrik Peter — Chief Medical Officer | Other (J): 10,000 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 31 @ $165.70 · Sale (S): 20 @ $166.32 · Sale (S): 141 @ $167.42 · Sale (S): 101 @ $168.64 · Sale (S): 105 @ $169.52 · Sale (S): 75 @ $170.58 · +3 more | EDGAR |
| 2026-04-23 | 4 | Chuang Hao-Yuan — Chief Financial Officer, Director | Other (J): 10,000 @ $0 | EDGAR |
| 2026-04-22 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 64 @ $163.49 · Sale (S): 78 @ $164.60 · Sale (S): 332 @ $165.49 · Sale (S): 312 @ $166.49 · Sale (S): 214 @ $167.34 | EDGAR |
| 2026-04-21 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 284 @ $162.76 · Sale (S): 524 @ $163.52 · Sale (S): 124 @ $164.40 · Sale (S): 40 @ $165.29 · Sale (S): 3 @ $166.91 · Sale (S): 16 @ $167.16 · +1 more | EDGAR |
| 2026-04-20 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 32 @ $158.46 · Sale (S): 52 @ $159.38 · Sale (S): 226 @ $160.55 · Sale (S): 274 @ $161.41 · Sale (S): 216 @ $162.48 · Sale (S): 200 @ $163.32 | EDGAR |
| 2026-04-20 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 216 @ $158.28 · Sale (S): 219 @ $159.81 · Sale (S): 201 @ $160.35 · Sale (S): 240 @ $161.61 · Sale (S): 76 @ $162.26 · Sale (S): 36 @ $163.21 · +1 more | EDGAR |
| 2026-04-16 | 4 | MATA NATHAN L. — Chief Scientific Officer | Sale (S): 383 @ $167.58 · Sale (S): 537 @ $168.64 · Sale (S): 68 @ $169.15 · Sale (S): 8 @ $170.76 · Sale (S): 4 @ $171.19 | EDGAR |
| 2026-04-13 | 4 | Lin Yu-Hsin — Chief Executive Officer, Director | Sale (S): 2,500 @ $180.36 · Sale (S): 3,500 @ $181.33 · Sale (S): 3,000 @ $182.40 · Sale (S): 200 @ $183 | EDGAR |
| 2026-04-13 | 4 | Chen Wan-Shan — Director | Sale (S): 1,100 @ $180.43 | EDGAR |
| 2026-04-13 | 4 | Chuang Hao-Yuan — Chief Financial Officer, Director | Sale (S): 2,000 @ $180.35 · Sale (S): 2,000 @ $181.40 · Sale (S): 1,909 @ $182.58 · Sale (S): 291 @ $183.08 | EDGAR |
| 2026-04-02 | 4 | Chen Wan-Shan — Director | Grant/award (A): 13,796 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Chuang Hao-Yuan — Chief Financial Officer, Director | Grant/award (A): 144,868 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | MATA NATHAN L. — Chief Scientific Officer | Grant/award (A): 144,868 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Lin Yu-Hsin — Chief Executive Officer, Director | Grant/award (A): 206,954 (derivative) @ $0 | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BLTE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →